Cardiovascular Benefits of Disease Modifying Therapies in Sickle Cell Disease: An Evolving Paradigm
SN Comprehensive Clinical Medicine · 07.08.2026 · 8 (1)
DOI: 10.1007/s42399-026-02573-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift SN Comprehensive Clinical Medicine, online erschienen am 07.08.2026. Verfasst von Ahmad Jalil und 6 weiteren Autor:innen. Die Arbeit nennt 59 Literaturangaben.
Abstract (Originalsprache)
Background
Sickle cell disease (SCD) is an inherited hemoglobinopathy characterized by red blood cell sickling, and recurrent vascular occlusion. Cardiovascular complications, including pulmonary hypertension and left ventricular dysfunction represent a major source of morbidity and mortality. So, increasing attention is being directed toward the cardiovascular effects of emerging therapies. This study aims to review the current evidence regarding the cardiovascular effects of disease-modifying therapies for sickle cell disease.
Methods
A narrative review of the published literature was conducted using different databases, including PubMed and Science direct. Studies evaluating the cardiovascular effects of sickle cell therapies including hydroxyurea, L-glutamine, crizanlizumab, voxelotor were reviewed to summarize current evidence on cardiovascular outcomes. Main Body Hydroxyurea, long considered standard therapy, demonstrates cardiovascular benefits by reducing left ventricular mass and chamber dilation, lowering pulmonary artery pressure, and enhancing nitric oxide signaling. L-glutamine, by mitigating oxidative stress, has been linked to improved cardiac function and reduced cardiovascular mortality in broader populations, though evidence in SCD remains limited. Voxelotor, once thought to be cardioprotective through reductions in cardiac biomarkers, was withdrawn from clinical use due to safety concerns. Crizanlizumab, a monoclonal antibody that decreases vaso-occlusive crises, may indirectly benefit cardiovascular health by lowering cumulative vascular stress, though direct data are lacking.
Conclusion
Cardiac complications significantly contribute to poor outcomes in SCD. Existing treatments such as hydroxyurea and glutamine provide measurable cardioprotective effects.Future research must prioritize dedicated trials assessing the impact of these therapies on cardiac structure and function to improve outcomes in this high-risk population.
Zitieren
APA
Jalil, A., Rajab, F., Srikaram, P., Mazhar, E., Mujahid, A., Rajab, H., & Amir, S. (2026). Cardiovascular Benefits of Disease Modifying Therapies in Sickle Cell Disease: An Evolving Paradigm. SN Comprehensive Clinical Medicine, 8(1). https://doi.org/10.1007/s42399-026-02573-8
Vancouver
Jalil A, Rajab F, Srikaram P, Mazhar E, Mujahid A, Rajab H, et al. Cardiovascular Benefits of Disease Modifying Therapies in Sickle Cell Disease: An Evolving Paradigm. SN Comprehensive Clinical Medicine. 2026;8(1). doi:10.1007/s42399-026-02573-8
BibTeX
@article{Jalil2026,
author = {Jalil, Ahmad and Rajab, Fatima and Srikaram, Prakhyath and Mazhar, Eisha and Mujahid, Aleena and Rajab, Hadia and Amir, Shiza},
title = {Cardiovascular Benefits of Disease Modifying Therapies in Sickle Cell Disease: An Evolving Paradigm},
journal = {SN Comprehensive Clinical Medicine},
year = {2026},
volume = {8},
number = {1},
doi = {10.1007/s42399-026-02573-8}
}
EUVIMED